MedTrace Logo

Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITP

NCT03998982 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-11

No results posted yet for this study

Summary

The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of glycyrrhetinic acid combining with high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune thrombocytopenia (ITP).

Conditions

Interventions

DRUG

Glycyrrhetinic Acid

Compound glycyrrhizin tablets 75 mg three times per day, 1 month

DRUG

Dexamethasone

HD-DXM (orally at 40 mg daily for 4d)

Sponsors & Collaborators

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou, MD,PhD · Shandong University Qilu Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2021-06-10
Completion
2021-06-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03998982 on ClinicalTrials.gov